MDL | MFCD00064201 |
---|---|
Molecular Weight | 195.22 |
Molecular Formula | C10H13NO3 |
SMILES | C[C@](C(O)=O)(N)CC1=CC=C(O)C=C1 |
Metyrosine acts by inhibiting tyrosine hydroxylase, thus causing depletion of adrenal stores of catecholamines [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Metyrosine (50-200 mg/kg; i.p.) reduces carrageenan inflammation
[1]
.
Metyrosine (50-200 mg/kg; i.p.) shows antiulcerative activity is 87.7%, 93.7% and 95.5% for 50, 100 and 200 mg/kg doses of metyrosine, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male albino Wistar rats (carrageenan-induced rat paw edema) [2] |
Dosage: | 50, 100 or 200 mg/kg |
Administration: | I.p. |
Result: | Reduced carrageenan inflammation at 50, 100 and 200 mg/kg doses (40%, 67% and 87%, respectively, at 4 h). |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01127503 | Bausch Health Americas, Inc. |
Velo-cardio-facial Syndrome|Psychosis
|
June 2010 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
H 2 O : 5 mg/mL ( 25.61 mM ; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 5.1224 mL | 25.6121 mL | 51.2243 mL |
5 mM | 1.0245 mL | 5.1224 mL | 10.2449 mL |
10 mM | 0.5122 mL | 2.5612 mL | 5.1224 mL |